key: cord-0808543-v0npcvgt authors: Krantz, Matthew S.; Liu, Yiwei; Phillips, Elizabeth J.; Stone, Cosby A. title: COVID‐19 vaccine anaphylaxis: PEG or not? date: 2021-06-15 journal: Allergy DOI: 10.1111/all.14722 sha: f09cdf77da65c1b7a62bfc2ba4617d630d1d745f doc_id: 808543 cord_uid: v0npcvgt nan To the Editor, In our prior work, we have described patients with immediate reactions to PEG3350. These reactions were consistent with anaphylaxis to PEG3350 bowel preparations and corticosteroids containing both PEG3350 and polysorbate (PS) 80 as an excipient (Table 1) . Aside from clinical presentation consistent with anaphylaxis, the case for these being IgE-mediated was supported by positive skin tests to both PEG3350 and PS80 (which we believe to be cross-reactive when primary sensitization occurs through PEG3350) as well as the presence of specific IgE (sIgE) against PEG by two independent methods. 2, 3 We would also like to highlight a case of anaphylaxis to an intravenous medication that might be mechanistically relevant. We observed a patient with a history to suggest preexisting PEG3350 anaphylaxis who also developed anaphylaxis when later exposed to a PEGylated liposome (PEGLip) microbubble, PEGLip 5000 perflutren echocardiogram contrast (Definity ® ). This case was also skin test positive to PEG3350 and PS80 as well as having demonstrable anti-PEG sIgE. 4, 5 In post-marketing surveillance of PEGLip perflu- In this same study, an alternative formulation of perflutren conjugated to human albumin (Optison ™ ), FDA approved in 1997, was also monitored and had no cases of anaphylaxis observed out of 12,219 doses administered. 7 Both formulations of perflutren carry a FDA black box warning for the risk of severe hypersensitivity reactions, but a hypothetical mechanism underlying these reactions had not been clearly elucidated or attributed prior to our report. While anaphylactic reactions to PEGLip perflutren appears to be rare overall, occurring in 0.006% of patients in the study by Wei et al, these reactions do occur. 6 PEG and/or lipid complexes in vitro have been shown to cause complement activation, and given the importance of these technologies for developing new therapeutics and vaccines, there is a science behind "PEG pairing" to minimize this effect. 8 However, our clinical and laboratory observations do support that IgE-mediated reactions can occur to a PEG-containing product presumably due to previous subclinical sensitization. These patients can notably be labeled as "idiopathic anaphylaxis" or multiple drug allergy if multiple episodes to different products occur over time without knowledge of the shared excipients. An additional observation by our group and others is that for immediate reactions associated with PEG there appears to be a molecular weight (MW) threshold. 9 This was seen in our skin test-positive patients who were positive to PEG3350 but negative to PEG300 who then tolerated oral challenge with PEG300. 2, 9 This MW predisposition may also vary by patient. To support this hypothesis, we have observed increasing binding avidity of anti-PEG sIgG as the molecular weight of the PEG increases. 2 Currently, IgE-mediated reactions associated with PEG appear to both uncommon and underrecognized. 2,4 PEG2000 is crucial to the formation of micelles used as the delivery system for the mRNA vaccines. It will be important to determine whether PEG2000 is im- (Table 1) . Understanding the mechanisms of immediate reactions associated with the Pfizer-BioNtech and any other mRNA vaccines that utilize different lipids in their PEG2000-micellar delivery system (Table 1) , should they occur, will be crucial not only for the safety of the current COVID-19 mRNA vaccine program but for mRNA vaccines in earlier stages of development for other viruses and cancer. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol? Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized Anti-PEG IgE in anaphylaxis associated with polyethylene glycol Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy Silver Springs, MD: US Food and Drug Administration The safety of definity and optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses Silver Springs, MD: US Food and Drug Administration Overcoming nanoparticle-mediated complement activation by surface PEG pairing Polyethylene glycol-induced systemic allergic reactions (anaphylaxis) COVID-19 vaccine anaphylaxis: PEG or not?